Cutler Group LP Provention Bio, Inc. Call Options Transaction History

Cutler Group LP

12 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q4 2022 Feb 07, 2023	BUY	$4.52 - $10.57 $12,203 - $28,539	2,700 New	2,700 $2,000
Q1 2022 Apr 14, 2022	SELL	$3.4 - $7.88 $116,280 - $269,496	-34,200 Reduced 66.15%	17,500 $5,000
Q4 2021 Jan 18, 2022	BUY	$5.59 - $7.39 $248,196 - $328,116	44,400 Added 608.22%	51,700 $1,000
Q3 2021 Oct 26, 2021	BUY	$5.66 - $8.33 $31,696 - $46,648	5,600 Added 329.41%	7,300 $3,000
Q2 2021 Jul 19, 2021	BUY	$6.71 - $11.04 $9,394 - $15,455	1,400 Added 466.67%	1,700 $4,000
Q1 2021 Apr 26, 2021	SELL	$10.12 - $19.45 $18,216 - $35,010	-1,800 Reduced 85.71%	300 $0
Q4 2020 Jan 21, 2021	SELL	$11.79 - $18.94 $38,907 - $62,502	-3,300 Reduced 61.11%	2,100 $6,000
Q3 2020 Oct 27, 2020	SELL	$10.34 - $15.2 $17,578 - $25,840	-1,700 Reduced 23.94%	5,400 $3,000
Q2 2020 Jul 22, 2020	BUY	$7.81 - $17.0 $37,488 - $81,600	4,800 Added 208.7%	7,100 $9,000
Q1 2020 May 07, 2020	SELL	$5.42 - $17.75 $20,054 - $65,675	-3,700 Reduced 61.67%	2,300 $0
Q4 2019 Feb 06, 2020	BUY	$5.84 - $14.9 $32,704 - $83,440	5,600 Added 1400.0%	6,000 $25,000
Q3 2019 Oct 28, 2019	BUY	$6.83 - $13.0 $2,732 - $5,200	400 New	400 $0

170K

Ticker PRVB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 81,549,904
Description
Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one...

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

Stay updated on Cutler Group LP with notifications on news.